Segall Bryant & Hamill LLC decreased its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 8.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 516,877 shares of the biotechnology company's stock after selling 45,898 shares during the quarter. Segall Bryant & Hamill LLC owned 0.36% of Aurinia Pharmaceuticals worth $4,642,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Barclays PLC raised its position in Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock valued at $1,607,000 after buying an additional 143,072 shares during the last quarter. PDT Partners LLC raised its holdings in shares of Aurinia Pharmaceuticals by 76.0% in the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company's stock valued at $2,210,000 after purchasing an additional 130,204 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Aurinia Pharmaceuticals by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after purchasing an additional 112,113 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Aurinia Pharmaceuticals by 22.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company's stock worth $4,997,000 after purchasing an additional 102,195 shares during the last quarter. Finally, American Century Companies Inc. grew its position in Aurinia Pharmaceuticals by 124.2% in the fourth quarter. American Century Companies Inc. now owns 171,590 shares of the biotechnology company's stock valued at $1,541,000 after purchasing an additional 95,066 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Stock Up 0.1 %
Shares of NASDAQ:AUPH traded up $0.01 during trading on Tuesday, hitting $8.05. 1,616,516 shares of the company were exchanged, compared to its average volume of 1,344,804. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -53.66 and a beta of 1.26. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The firm has a fifty day moving average price of $8.10 and a two-hundred day moving average price of $8.07.
Insider Buying and Selling
In other news, insider Greg Keenan sold 12,239 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the sale, the insider now directly owns 161,789 shares of the company's stock, valued at $1,294,312. This trade represents a 7.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Joseph M. Miller sold 61,859 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. The trade was a 8.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,898 shares of company stock worth $2,753,094. Insiders own 4.30% of the company's stock.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.
Get Our Latest Stock Report on AUPH
Aurinia Pharmaceuticals Profile
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
